Crispr Therapeutics AG (CRSP) Stock Forecast & Price Target
Crispr Therapeutics AG · NASDAQ
$47.57+0.84 (+1.80%)
15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 14 firms covering Crispr Therapeutics AG, 9 rate it Buy or better, 5 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets range widely, $44.00 to $110.00 (about 2.5x), a sign of real disagreement on valuation. The average target of $71.29 sits 50% above the current $47.57. The rating mix has stayed broadly stable, with Buy-side ratings easing from 10 to 9 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-1.19 next quarter toward $-3.89 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS14 ratings
Moderate Buy
Strong Buy00%
Buy964%
Hold536%
Sell00%
Strong Sell00%
Based on 14 analysts giving stock ratings to Crispr Therapeutics AG.
As of Jul, 9 of 14 firms rate CRSP a Buy (5 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
CRSP EPS & revenue forecast
EPS · NEXT QUARTER
$-1.19
Range $-1.72 – $-0.35 · 18 analysts · +1% YoY
Next period, 18 analysts expect Crispr Therapeutics AG to earn $-1.19 a share (range $-1.72 – $-0.35), versus $-1.17 a year earlier. Full-year consensus is $-4.88, growing to $-3.89 the year after.
REVENUE · NEXT QUARTER
$16.6M
Range $0 – $125.4M · 18 analysts · +1768% YoY
Revenue is expected to reach $16.6M (range $0 – $125.4M), +1768.0% year-over-year. Full-year consensus is $40.1M, rising to $162.8M next year.
Top analysts covering Crispr Therapeutics AG
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CRSP.
#1
Silvan Tuerkcan
JMP Securities · Rank #29
Buy
$80.00+68.2% to target
Overall win rate
50%
+ Follow
#2
Geulah Livshits
Chardan Capital · Rank #100
Buy
$76.00+59.8% to target
Overall win rate
44%
+ Follow
#3
Yigal Nochomovitz
Citigroup · Rank #131
Buy
$82.00+72.4% to target
Overall win rate
43%
+ Follow
#4
Mitchell Kapoor
HC Wainwright & Co. · Rank #165
Buy
$80.00+68.2% to target
Overall win rate
34%
+ Follow
#5
Edward Tenthoff
Piper Sandler · Rank #277
Buy
$110.00+131.2% to target
Overall win rate
29%
+ Follow
CRSP stock forecast FAQ
What is CRSP's average 12-month price target?+
The 14 analysts with a live target average $71.29 for Crispr Therapeutics AG over the next 12 months, ranging from a $110.00 high to a $44.00 low.
Is CRSP stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 14 analyst ratings, 9 are Buy or Strong Buy, 5 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for CRSP?+
The Street-high target is $110.00 (Piper Sandler), and the Street-low is $44.00 (Baird). The average of all 14 active targets is $71.29.
How many Wall Street analysts cover CRSP?+
14 analysts have an active rating on Crispr Therapeutics AG, and 14 firms carry a live 12-month price target.
Who is the most accurate analyst covering CRSP?+
Among analysts who currently cover CRSP, Silvan Tuerkcan of JMP Securities has the strongest overall Quantellect track record (Rank #29). Their current call is Buy with a $80.00 target.
What is Crispr Therapeutics AG's projected EPS for next quarter?+
The consensus estimate is $-1.19 per share (range $-1.72 – $-0.35) across 18 analysts. Full-year EPS is projected at $-4.88, rising to $-3.89 the following year.
How much revenue is Crispr Therapeutics AG expected to report next quarter?+
Consensus revenue is $16.6M (range $0 – $125.4M). Full-year revenue is projected at $40.1M, growing to $162.8M next year.
Have analysts been upgrading or downgrading CRSP lately?+
As of Jul, 9 of 14 firms rate CRSP a Buy (5 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CRSP calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
